The pre-IPO subscription period in Prostatype Genomics AB's issue of securities ended on October 1, 2020.
Solna/SwedenOctober 6, 2020 -The pre-IPO subscription period in Prostatype Genomics AB's ("Prostatype Genomics" or "the Company") issue of securities, consisting of shares and associated warrants, prior to listing at Nasdaq First North Growth Market ("FirstNorth") ended on October 1, 2020. The issue of securities was oversubscribed by over 200 percent.
The first day of trading in Prostatype Genomics shares and warrants on Nasdaq FirstNorth Growth Market is expected to be Tuesday, October 27, 2020. The shares will be traded under the short name "PROGEN" with ISIN code SE0014684569. The warrants will be traded under the short name "PROGEN TO1" with ISIN code SE0014956462.
The Securities Commission acted as financial advisor and Markets & Corporate Law Nordic AB acted as legal advisor in connection with the IPO. Nordnet Bank AB are the Selling Agent.
Prostatype Genomics CEO Fredrik Persson comments:
“We are pleased with the positive outcome and can state with the proceeds from the issue that we are now well prepared for our upcoming expansion. The need to be able to assess the development of prostate cancer for the individual patient is enormous and through our Prostatype® test kit we can help to give patients a better quality of life while reducing healthcare costs. Together with our new shareholders, we now look forward introducing Prostatype Genomics into more markets. ”
KarlheinzSchmelig, Managing Partner at Creathor Ventures and member of the supervisory board at Prostatype Genomics AB comments:
“We have been invested in Prostatype Genomics since 2013 and are very happy to support the company further in this exciting next step to bring this groundbreaking diagnostic tool to patients and doctors world wide”
About Prostatype Genomics AB:
ProstatypeGenomics provide Prostatype is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institute and is provided by Prostatype Genomics AB. For more information about Prostatype Genomics AB, visit www.prostatypegenomics.com.
For further information please contact:
Fredrik Persson, CEO
Phone:+46 (0) 73 049 77 01
Email: fredrik.persson@prostatypegenomics.com
About Creathor Ventures
Creathor Ventures invests in technology-oriented companies that drive the automation of industry and business, and the personalization and digitalization of healthcare. From its offices in Germany and Switzerland, the team currently supports over 30 tech and healthcare companies. Over the past 30 years, the management team has financed over 200 companies as lead or co-lead investor. More than 20 companies have been listed on international stock exchanges. Creathor Ventures currently manages a fundvolume of over 230 million euros. Further information can be found at: www.creathor.com
For further informations please contact:
Karlheinz Schmelig
Managing Partner
Phone: +49 6172 139720
Email: karlheinz.schmelig@creathor.com
For more information about the issue andthe planned listing, please contact:
Fund Commission
Phone: +46 (0) 40 615 1410
Email: info@sedermera.se